SCHEMBL6013616

SCHEMBL6013616

COc1ccc([C@@H]2CC(=O)c3c(OC(C)=O)cc(OC(C)=O)cc3O2)cc1OC(C)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 2/20 0.56
MAPK1 P28482 2/20 0.56
HSD17B10 Q99714 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ABCG2 Q9UNQ0 1/20 0.56
TAS2R31 P59538 2/20 0.56
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
CYP19A1 P11511 3/20 0.53
TP53 P04637 2/20 0.53
XDH P47989 2/20 0.53
CYP1A1 P04798 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP1B1 Q16678 2/20 0.53
MAPT P10636 2/20 0.53
ATM Q13315 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151033 0.95 BCHE (0.58) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL31022637 0.88 BCHE (0.69) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL29477373 0.88 BCHE (0.69) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL6726368 0.88 BCHE (0.69) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL6726363 0.88 BCHE (0.69) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL10005478 0.84 TAS2R31 (0.51) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL5857357 0.83 ALDH1A1 (0.76) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL28381344 0.83 BCHE (0.57) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL23813679 0.80 BCHE (0.64) CYP3A4ALDH1A1HPGDMAPK1HSD17B10
SCHEMBL11640358 0.80 CYP3A4 (0.59) CYP3A4ALDH1A1MAPK1CYP19A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4105675-A REDUCING ACYLATED FLAVANONE WITH ALKALI BOROHYDRIDE TO REMOVE OXYGEN FUNCTION AT 4-POSITION; OXIDIZING WITH HALOGENATED BENZOQUINONE TO FORM SALT THE COCA-COLA COMPANY (US) 1978-08-08 US claimed
US-20060229358-A1 Pharmaceutical composition containing flavonoids TAIPEI MEDICAL UNIVERSITY (TW) 2006-10-12 US disclosed
US-4105675-A REDUCING ACYLATED FLAVANONE WITH ALKALI BOROHYDRIDE TO REMOVE OXYGEN FUNCTION AT 4-POSITION; OXIDIZING WITH HALOGENATED BENZOQUINONE TO FORM SALT THE COCA-COLA COMPANY (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229358-A1 Pharmaceutical composition containing flavonoids PDE4B, PDE4A, PDE3B CYP3A4 12/4885ALDH1A1 1668/4885HPGD 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.